ONC (BeOne Medicines Ltd.) Stock Financials & Earnings | Market Cap Arena

ONC (BeOne Medicines Ltd.) Stock Financials & Earnings | Market Cap Arena

ONCBeOne Medicines Ltd.

Mkt Cap$33B

Healthcare·Medical - Pharmaceuticals·🇺🇸 United States·NASDAQ

Revenue (TTM)$5.3B

Net Income (TTM)$287M

EPS (TTM)$21.52

Free Cash Flow (TTM)$613M

Gross Margin87.5%

Op. Margin8.4%

Net Margin5.4%

FCF Margin11.5%

P/S Ratio (TTM)6.2x

P/E Ratio (TTM)114.7x

YoY Rev Growth+40.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$448M	$366M	-$371M
Q2 23	$595M	$499M	-$319M
Q3 23	$781M	$685M	-$134M
Q4 23	$634M	$529M	-$384M
Q1 24	$752M	$627M	-$261M
Q2 24	$929M	$791M	-$107M
Q3 24	$1.0B	$831M	-$120M
Q4 24	$1.1B	$967M	-$79M
Q1 25	$1.1B	$952M	$11M
Q2 25	$1.3B	$1.2B	$88M
Q3 25	$1.4B	$1.2B	$163M
Q4 25	$1.5B	$1.4B	$185M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	21.1x	—
Q2 23	18.2x	—
Q3 23	14.9x	—
Q4 23	13.4x	—
Q1 24	11.9x	—
Q2 24	10.6x	—
Q3 24	9.9x	—
Q4 24	8.6x	—
Q1 25	7.9x	—
Q2 25	7.2x	—
Q3 25	6.6x	480.3x
Q4 25	6.2x	114.7x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$564M	-$689M
Q2 23	-$294M	-$415M
Q3 23	-$78M	-$260M
Q4 23	-$222M	-$389M
Q1 24	-$309M	-$502M
Q2 24	-$96M	-$206M
Q3 24	$188M	$55M
Q4 24	$75M	-$17M
Q1 25	$44M	-$72M
Q2 25	$264M	$200M
Q3 25	$403M	$354M
Q4 25	$417M	$131M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$126M
Q2 23	$121M
Q3 23	$182M
Q4 23	$167M
Q1 24	$193M
Q2 24	$110M
Q3 24	$134M
Q4 24	$92M
Q1 25	$116M
Q2 25	$64M
Q3 25	$48M
Q4 25	$286M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+46.0%	+9.2%
Q2 23	+74.3%	+17.0%
Q3 23	+101.6%	+10.8%
Q4 23	+66.9%	+20.0%
Q1 24	+67.9%	+23.7%
Q2 24	+56.1%	+13.4%
Q3 24	+28.2%	+22.6%
Q4 24	+77.8%	+18.6%
Q1 25	+48.6%	+9.2%
Q2 25	+41.6%	+18.4%
Q3 25	+41.0%	+11.3%
Q4 25	+32.8%	+8.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$75M	16.8%
Q2 23	$103M	17.4%
Q3 23	$96M	12.3%
Q4 23	$93M	14.6%
Q1 24	$89M	11.8%
Q2 24	$131M	14.1%
Q3 24	$115M	11.5%
Q4 24	$108M	9.5%
Q1 25	$95M	8.5%
Q2 25	$151M	11.5%
Q3 25	$141M	10.0%
Q4 25	$757M	50.5%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$409M	$328M
Q2 23	$423M	$395M
Q3 23	$453M	$366M
Q4 23	$494M	$417M
Q1 24	$461M	$427M
Q2 24	$454M	$444M
Q3 24	$496M	$455M
Q4 24	$542M	$505M
Q1 25	$482M	$459M
Q2 25	$525M	$538M
Q3 25	$524M	$529M
Q4 25	$615M	$555M

Revenue by Geography

Quarter	All Other Countries Except China And United States Of America	China	Europe	United States
Q1 25	$32M	$400M	$119M	$567M
Q2 25	$36M	$433M	$152M	$694M
Q3 25	$51M	$440M	$167M	$755M
Q4 25	—	$407M	$174M	$864M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$3.5B	$294M	$3.8B
Q2 23	$3.4B	$106M	$3.5B
Q3 23	$3.1B	$107M	$3.2B
Q4 23	$3.2B	$3M	$3.2B
Q1 24	$2.8B	$0	$2.8B
Q2 24	$2.6B	$0	$2.6B
Q3 24	$2.7B	$0	$2.7B
Q4 24	$2.6B	$0	$2.6B
Q1 25	$2.5B	$0	$2.5B
Q2 25	$2.8B	$0	$2.8B
Q3 25	$4.0B	$0	$4.0B
Q4 25	$4.5B	$0	$4.5B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	104M	+0.4%
Q2 23	105M	+0.4%
Q3 23	107M	+2.2%
Q4 23	104M	-2.7%
Q1 24	104M	+0.2%
Q2 24	105M	+0.4%
Q3 24	105M	+0.0%
Q4 24	106M	+1.5%
Q1 25	111M	+4.6%
Q2 25	113M	+1.5%
Q3 25	115M	+1.5%
Q4 25	113M	-0.9%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	$37K	240
FY 16	$3K	348
FY 17	$265K	900
FY 18	$90K	2K
FY 19	$122K	4K
FY 20	$58K	5K
FY 21	$143K	8K
FY 22	$154K	9K
FY 23	$232K	11K
FY 24	$346K	11K
FY 25	$445K	12K